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We investigated the prevalence of cystic fibrosis-related diabetes (CFRD) and its association with various demographic and clinical conditions
in a Dutch child and adult cystic fibrosis (CF) population.
Patients were classified as having either normal glucose tolerance (NGT), impaired glucose tolerance (IGT) or CFRD. Associations with the
following parameters were studied: age, gender, BMI, mutations, pulmonary function, infection status, and hospitalization.
In our patient population the prevalence of IGT and CFRD was 16% and 31% respectively. After excluding pancreatic sufficient patients, the
prevalence of CFRD was 40% and in patients over 40 years 52%. Compared with patients with NGT, CFRD patients were older, had more in-
hospital days and had worse pulmonary function. Women developed CFRD at a significantly younger age than men.
CFRD is a frequently occurring co-morbidity in patients with CF. The prevalence of CFRD is increasing in ageing CF populations and
deserves rising attention in CF management.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis (CF); Cystic fibrosis-related diabetes (CFRD); Diabetes mellitus; Oral glucose tolerance test (OGTT)1. Introduction
Over the past 50 years, cystic fibrosis (CF) has evolved from
a lethal children's disease towards a chronic illness in children
and adults with a current life expectancy in excess of 35 years
[1]. Increased survival has led to a rise in cystic fibrosis-related
diabetes (CFRD) [2]. CFRD appears primarily in CF patients
with an exocrine pancreatic insufficiency (PI) and consists of a
combination of relative insulin deficiency and insulin resistance
[3]. CFRD is associated with faster deterioration in lung
function, even years before diagnosis and poorer survival in
comparison to non-diabetic CF patients [4–6].
The aim of this cross-sectional study was to investigate the
prevalence of CFRD in our CF population and especially in PI⁎ Corresponding author. Tel.: +31 702102203; fax: +31 702102150.
E-mail address: j.m.w.vandenberg@hagaziekenhuis.nl
(J.M.W. van den Berg).
1569-1993/$ - see front matter © 2009 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2009.04.010patients. Additionally, we investigated the relationship
between presence of CFRD and various clinical conditions in
PI patients.
2. Methods
In 2007, a total of 226 CF patients (49 children (b18 years)
and 177 adults) visited our Cystic Fibrosis Center in The Hague.
In all patients, CF diagnosis was confirmed by positive
genotyping or raised sweat chloride at sweat testing. According
to European consensus, oral glucose tolerance testing (OGTT)
is recommended in CF patients over 10 years with pancreatic
insufficiency [7]. Therefore, all 202 patients older than 10 years
were enrolled, including three post-transplanted patients.
All non-diabetic PI CF patients underwent a modified 75 g
OGTT after overnight fasting [8]. Only tests performed during
stable disease were included and defined as having no pulmonary
exacerbations needing oral or intravenous antibiotic treatment in
the past 4 weeks. Oral corticosteroid use was exceptional. Patients
were classified using the WHO Criteria for OGTT; 1) normald by Elsevier B.V. All rights reserved.
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glucose (2hBG)b7.8), 2) impaired glucose tolerance (IGT:
FBGb7.0; 2hBG 7.8–11.1) and 3) CFRD with fasting
hyperglycaemia (FBGN7.0) or CFRD without fasting hypergly-
caemia (FBGb7.0; 2hBGN11.1) [9]. No second OGTT was
performed, instead newly diagnosed CFRD was confirmed by
glucose self-monitoring. Known CFRD was defined as chroni-
cally use of insulin.
Clinical data was collected from patients' hospital reviews.
Known CFTR mutations were divided into 5 subclasses [10].
Pulmonary function tests included forced expiratory volume in
1 s (FEV1) and forced vital capacity (FVC), expressed as
percentage of predicted. Body mass index (BMI; kg/m2) and
pulmonary function were measured on the same occasion as the
OGTT. Exocrine pancreatic insufficiency was defined as
requirement of pancreatic enzyme replacement identified by
faecal pancreatic elastase measurement. Chronic Pseudomonas
aeruginosa infection was defined as three consecutive positive
sputum cultures over 6 months and Burkholderia cepacia
infection as one positive sputum culture in the past. Allergic
bronchopulmonary aspergillosis (ABPA) was defined as a
period of ABPA in the past and diagnosed clinically.
Hospitalization was defined as number of in-hospital days
during the preceding year.Table 1
Baseline characteristics.
Total population PI patient
Total
Number of patients 202 148
Gender–% male 49 50
Age–years (range) 31.5 (10–68) 29.0 (10–
BMI–kg/m2±SD 21.5±2.6 20.9±2.4
Pancreatic status–% PI 73 100
FEV1% predicted (range) 63.5 (17.0–120.0) 61.5 (17.0
FEV1% predicted 10–17 years (n=23) 93.8 93.8
FEV1% predicted 18–30 years (n=61) 67.5 67.0
FEV1% predicted 31–40 years (n=45) 59.0 52.0
FEV1% predicted N40 years (n=19) 56.0 51.0
FVC% predicted (range) 86.0 (34.0–145.0) 85.0 (38.0
FVC% predicted 10–17 years (n=23) 96.2 96.2
FVC% predicted 18–30 years (n=61) 84.8 84.6
FVC% predicted 31–40 years (n=45) 80.0 78.0
FVC% predicted N40 years (n=19) 89.0 85.0
Class of mutation
Class I–% 9 11
Class II–% 44 61
Class III–% 2 3
Class IV–% 6 6
Class V–% 22 5
Class unknown–% 17 14
Homozygous ΔF508–% 43 65
Chronic P. aeruginosa infection–% 66 70
B. cepacia infection–% 4 4
ABPA–% 17 18
In-hospital days in previous year–mean (range) 10.4 (0–166) 13.0 (0–1
*pb0.05 versus NGT, **pb0.01 versus NGT, †trend versus NGT (trend was defi
NGT=normal glucose tolerance; IGT=impaired glucose tolerance; CFRD=cystic
expiratory volume in 1 s as % of predicted; FVC% predicted= forced vita
B. cepacia=Burkholderia cepacia; ABPA=allergic bronchopulmonary aspergillosis2.1. Statistical analysis
All frequencies listed are median values, unless otherwise
stated. A Kruskall–Wallis test was performed for identifying
differences between three groups and aWilcoxon–Mann–Whitney
test for post-hoc analysis. Categorical variables were compared by
Chi-Square testing. Variables that showed significant correlation
with pb0.10, were included for backward multiple regression
analysis to evaluate determinants of CFRD. Data was analysed
with SPSS 14.0 statistical package (SPSS Inc., Chicago, IL, USA).
3. Results
In the total study population, IGTand CFRD were observed in
32 (16%) and 62 (31%) patients, respectively. Three patients (6%)
with exocrine pancreatic sufficiency (PS) had type 1 diabetes
mellitus, two of them had proven islet cell antibodies. All newly
diagnosed CFRD patients had diabetic blood sugars during blood
glucose self-monitoring. Since diabetes in PS patients is
considered probably non-CF related [3], all 54 PS patients were
excluded for further analysis (Table 1). Of the 148 PI CF patients,
57 (38%) had NGT, 32 (22%) had IGT and 59 (40%) had CFRD
(including 11 newly diagnosed patients in 2007) (Table 1). CFRD
prevalence increased with age, with a prevalence of 22% ins
NGT IGT CFRD
57 32 59
47 53 51
66) 27.0 (10–49) 29.0 (10–66) 31.0 (10–54)*
20.9±2.2 21.7±2.9 20.7±2.3
100 100 100
–120.0) 75.0 (22.0–118.8) 60.0 (21.0–120.0) 54.0 (17–111.5)**
98.0 93.7 86.6
69.0 54.5† 54.5
54.0 60.5 49.5
47.0 55.5 52.5
–137.0) 95.0 (47.0–133.6) 79.5 (49.0–137.0)* 81.0 (38.0–126.0)**
98.2 92.6† 87.7
92.0 72.5† 82.5
83.0 79.5 73.5†
76.0 81.5 88.5
12 9 10
51 63 70
2 3 3
9 9 2
9 3 2
17 13 13
49 63 68†
63 63 80†
4 3 5
12 12 25
66) 6.8 (0–166) 10.1 (0–48)* 20.8 (0–150)**
ned as p-value between 0.05 and 0.1); PI=exocrine pancreatic insufficiency;
fibrosis-related diabetes; BMI=body mass index; FEV1% predicted=forced
l capacity as % of predicted; P. aeruginosa=Pseudomonas aeruginosa;
.
Fig. 1. Glucose tolerance categories in CF patients with exocrine pancreatic
insufficiency, prevalence within age groups. NGT=normal glucose tolerance;
IGT=impaired glucose tolerance; CFRD=cystic fibrosis-related diabetes;
n=number of patients.
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40 years (Fig. 1). In CFRD patients the median duration of insulin
therapy was 3.5 years (range 0–24 years). The median age of
CFRD diagnosis was 24.5 years (range 10–50 years).
Between patients with IGT and patients with CFRD no
statistical differences were found in demographics. However,
as compared to CF patients with NGT, CFRD patients were
older (p=0.022), had worse FEV1 (pb0.001) and FVC
(p=0.027) levels and had more in-hospital days (p=0.002).
Patients with NGT tended to show less chronic P. aeruginosa
infections (p=0.075) and had a lower prevalence of homo-
zygosity for the ΔF508 mutation (p=0.052). No differences
were found for gender, BMI, ABPA or B. cepacia infections.
Since age is a possible confounder, pulmonary function was
compared within different age groups. Between these sub-
groups no significant differences were found (Table 1). For
backward logistic regression analysis, patients with IGT and
CFRD were compared to patients with NGT. Age and number
of in-hospital days were predictors for having an abnormal
glucose tolerance, however with small odds (OR respectively
1.051 and 1.024).Table 2
Differences between men and women with CFRD.
Men
Number of patients 30
Age–years (range) 32.0 (17–54)
Age of CFRD onset–years (range) 27.5 (15–50)
Duration of insulin therapy–years (range) 3.0 (0–24)
BMI–kg/m2±SD 21.70±2.4
FEV1% predicted (range) 52.0 (17.0–1
FVC% predicted (range) 81.0 (60.6–1
Homozygous ΔF508–% 80
Chronic P. aeruginosa infection–% 83
B. cepacia infection–% 10
ABPA–% 20
In-hospital days in previous year–mean (range) 14.0 (0–150)
NS=not significant; CFRD=cystic fibrosis-related diabetes; BMI=body mass index
predicted=forced vital capacity as % of predicted; P. aeruginosa=Pseudomonas aer
aspergillosis.Betweenmen andwomen a significant differencewas found in
age of CFRD diagnosis, with a median age of 19.5 years in
women, whereas in men this was 27.5 years (p=0.008). Women
also spent more days in the hospital (27.9 vs. 14.0 days, p=0.008)
(Table 2).
4. Discussion
The aim of this study was to investigate CFRD prevalence in a
CF patient population. CFRD was seen in 31% of the total
population and in 40% of the PI CF patients. Associations with
CFRD presence were found for age and in-hospital days. Women
developed CFRD at a younger age in comparison to men.
Various studies report influential conditions on the develop-
ment and presence of CFRD. Associations were found
especially for age, gender, pulmonary function, pancreatic
dysfunction, corticosteroid use and CFTR mutation severity
[11–14]. The incidence of PS in our population is relatively
high. This may be explained by the high incidence of the mild
CFTR-mutation A445E which is the second most common
mutation in The Netherlands [15]. We deliberately excluded all
PS patients, since PS is strongly associated with milder genetic
mutations and milder disease and development of CFRD is
unlikely [10,16]. By excluding all PS patients, only patients
truly at risk for CFRD were selected. After exclusion, only age
and in-hospital days were positive predictors for the presence of
CFRD.
Pulmonary function was also associated with the presence of
CFRD, but age was a possible confounder. Prevalence of CFRD is
higher in older patients and pulmonary function in older patients is
lower. We compared pulmonary function within different age
groups and observed no significant differences between the
different glucose tolerances. Alternatively, this might be explained
by small patient numbers in the subgroups.
A remarkable outcome was the difference observed between
men and women with CFRD. Although the number of male and
female CFRD patients was similar, women were significantly
younger and developed CFRD at a younger age [5,17,18]. This
does not only show that female patients develop CFRD at aWomen p-value
29 NS
29.0 (10–49) p=0.045
19.5 (10–45) p=0.008
4.5 (0–24) NS
20.0±2.2 NS
01.0) 55.8 (24.0–111.5) NS
26.0) 76.0 (38.0–123.0) NS
55 p=0.052
76 NS
3 NS
31 NS
27.9 (0–109) p=0.008
; FEV1% predicted=forced expiratory volume in 1 s as % of predicted; FVC%
uginosa; B. cepacia=Burkholderia cepacia; ABPA=allergic bronchopulmonary
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hypothesis of the detrimental influence of CFRD on life
expectancy [5,6]. Female CF patients are generally known to
have a lower survival rate [19]. However, no explanation has so
far been found for the earlier CFRD onset in female patients.
Female hormones and early puberty onset are likely to play a
role in this disadvantage and use of oral contraceptives has also
been associated with CFRD development [17].
Performing a meta-analysis of the different studies reporting
on CFRD prevalence would be a difficult task, since inclusion
criteria vary. In comparison to other studies, our CFRD
prevalence is fairly high. CFRD prevalence in two large studies
was 4.9% and 17%, respectively [18,1]. Smaller studies report
CFRD prevalence of 12%, 15%, 32%, and 54%, respectively
[6,20–22]. The higher prevalence in our study is probably due
to the relatively old population, the exclusion of PS patients and
the exclusion of patients under 10 years. The reason patients
younger than 10 years were excluded is the low incidence of
CFRD in this age group and that an OGTT is only performed in
symptomatic under tens.
In conclusion, CFRD is a frequently occurring co-morbidity
in CF. Prevalence of CFRD is increasing in ageing CF
populations, with 40% CFRD in all PI patients in our study
with women developing CFRD at a younger age compared to
men.
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